Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy
Proceedings of the National Academy of Sciences · 22.04.2025 · 122 (16)
DOI: 10.1073/pnas.2501791122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 16.04.2025. Verfasst von Jennie Lugassy und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Faculty of Medicine, Technion, Haifa 3525422, Israel. Hauptthemen laut MEDLINE: Chemokine CXCL9, Chemokine CXCL10, Dipeptidyl Peptidase 4, Immunotherapy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: DKFZ, Israel Cancer Research Fund (ICRF), Israel Science Foundation (ISF).
Abstract (Originalsprache)
CXCR3 is a chemokine receptor for three ligands: CXCL9, CXCL10, and CXCL11. Accumulating evidence, including data presented here, suggests that the interaction between CXCL9/CXCL10 and CXCR3 not only attracts CXCR3+ T cells but also promotes the induction of IFNγ- high effector/cytotoxic CD4+ and CD8+ T cells, establishing a CXCL9/10-CXCR3-IFNγ self-amplifying cycle that promotes efficient cancer cell killing. One of the homeostatic mechanisms that may limit this cycle is the cleavage of the two N-terminal amino acids of these chemokines by Dipeptidyl Peptidase IV (DPP-4). The modified chemokines retain their ability to bind CXCR3 but no longer activate it, becoming competitive antagonists to native CXCL9/CXCL10. To develop a DPP-4-resistant variant, we combined biochemical analysis with computational modeling, demonstrating that the addition of N-terminal glutamine (Q) to CXCL9-Fc and CXCL10-Fc rendered them fully active CXCR3 agonists, yet resistant to DPP-4 cleavage. Preclinical evaluations imply that they offer significant therapeutic potential in cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Faculty of Medicine, Technion, Haifa 3525422, Israel.
- Research and Development, Teva Pharmaceutical Industries, Ltd., Netanya 4250419, Israel.
- Biologics Discovery, Teva Pharmaceutical Industries Ltd., Redwood City, CA 94063.
ORCID-Profile: Daniel Saidemberg, Gabriela Ridner-Bahar, Nir Berger, Nathan Karin
Förderung
- DKFZ
- Israel Cancer Research Fund (ICRF)
- Israel Science Foundation (ISF)
- Israel Innovation authority
Zitieren
APA
Lugassy, J., Abdala-Saleh, N., Jarrous, G., Turky, A., Saidemberg, D., Ridner-Bahar, G., Berger, N., Bar-On, D., Taura, T., Wilson, D., & Karin, N. (2025). Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy. Proceedings of the National Academy of Sciences, 122(16). https://doi.org/10.1073/pnas.2501791122
Vancouver
Lugassy J, Abdala-Saleh N, Jarrous G, Turky A, Saidemberg D, Ridner-Bahar G, et al. Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy. Proceedings of the National Academy of Sciences. 2025;122(16). doi:10.1073/pnas.2501791122
BibTeX
@article{Lugassy2025,
author = {Lugassy, Jennie and Abdala-Saleh, Noor and Jarrous, Ghada and Turky, Abeer and Saidemberg, Daniel and Ridner-Bahar, Gabriela and Berger, Nir and Bar-On, Dana and Taura, Tetsuya and Wilson, David and Karin, Nathan},
title = {Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
volume = {122},
number = {16},
doi = {10.1073/pnas.2501791122}
}
EUVIMED